Change in fair value of warrant 5,760,000 -
Stock-based compensation 791,908 1,290,286
Deferred rent and credit on lease
concession (187,094) (25,889)
Amortization of premium on
marketable securities (8,244) (60,642)
Loss on disposal of fixed assets 17,174 -
Changes in:
Accounts receivable (15,868) (2,467,478)
Inventories 231,760 244,566
Prepaid expenses and other
current assets (818,622) 49,456
Deposits other than on property
and equipment, and other assets 63,366 37,843
Accounts payable (191,582) 216,562
Accrued expenses (268,782) (3,239,993)
Deferred product revenue - 1,989,644
Net cash used in operating
activities (10,471,092) (23,176,584)
Cash flows from investing activities:
Purchases of marketable securities (2,363,866) (5,867,518)
Sale and maturities of marketable
securities - 500,000
Purchases of property and equipment - (19,592)
Deposits on property and equipment - (1,150,625)
Proceeds from sale of fixed assets 331,867 -
Net cash used in investing
activities (2,031,999) (6,537,735)
Cash flows from financing activities:
Proceeds from private placement of
common stock, net of issue c
'/>"/>
| SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |